Jenny Rooke, PhD, started the investment company Genoa Ventures out of frustration. As a geneticist, she saw firsthand how the tools powering life sciences and healthcare lag far behind the complexity of real biology. After stints in industry and investing, Rooke launched the venture capital firm eight years ago to back deeply technical founders building the infrastructure for better biology—tools and platforms that rarely get funded in a world obsessed with therapeutics. Genoa’s core belief is that precision medicine is rooted in informed medicine: integrating molecular, physiological, and multimodal data to guide diagnosis, treatment choice, dosing, and monitoring over time.
During the 2026 J.P. Morgan Healthcare Conference, Rooke described Genoa’s investment lens as disciplined, platform-driven product development. In this video with Inside Precision Medicine, Rooke argues that aren’t businesses on their own—they’re engines that generate focused, high-value products and durable pipelines. She highlighted companies like InterVenn, which uses glycoproteomics to bring sharper specificity to cancer triage, and Aqtual, which reads system-wide biological activation from circulating DNA fragment patterns to guide therapy selection in chronic disease. Across diagnostics, biomarkers, neuromodulation, and clinical-grade data, Genoa Ventures is making a clear bet: multimodal insight beats single answers.
Â
